← Back to Search

Crosslinking Agent

Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system. for Keratoconus

Phase 2
Waitlist Available
Led By David Lubeck, MD
Research Sponsored by Arbor Center for Eye Care
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will test a new device to treat corneal thinning. The goal is to see if it is safe and effective.

Eligible Conditions
  • Keratoconus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean keratometry in diopters
Secondary outcome measures
Best corrected visual acuity

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Pulsed, acceleratedExperimental Treatment1 Intervention
18mW, 5 seconds on, 5 seconds off, 10 minutes of illumination.
Group II: ConventionalActive Control1 Intervention
9mW continuous, 10 minutes of illumination.

Find a Location

Who is running the clinical trial?

Arbor Center for Eye CareLead Sponsor
David Lubeck, MDPrincipal InvestigatorArbor Center for Eye Care

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have enrolled for participation in this research endeavor?

"Affirmative. Clinicaltrials.gov confirms that this clinical research, which was originally advertised on July 8th 2020, is still actively enrolling participants. The study requires 100 individuals from a single location to participate in the trial."

Answered by AI

What potential risks could patients encounter due to Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system?

"After careful analysis, our team at Power ranked Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system a 2 on safety. This is due to available data supporting its safety but no evidence of efficacy yet."

Answered by AI

Does the criteria for inclusion in this trial encompass individuals over thirty years of age?

"This clinical trial is recruiting participants between the age of 12 and 60. Additionally, there are 45 trials for minors under 18 years old and 182 for seniors above 65."

Answered by AI

Is my inclusion viable for this medical research project?

"To qualify for inclusion in this trial, applicants must have keratoconus and fall between the age range of 12 to 60. Recruitment is expected to involve 100 patients."

Answered by AI

Is it possible to enroll in this experimental trial at the moment?

"Currently, clinicaltrials.gov indicates that this medical trial is open to participants. The study was initially published on July 8th 2020 and has since been updated as recently as March 16th 2022."

Answered by AI

Who else is applying?

What state do they live in?
Missouri
What site did they apply to?
Arbor Center for Eye Care
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
1
Recent research and studies
clinicaltrials.govStudy
Safety and Efficacy of Corneal Crosslinking Using the PXL-Platinum 330 for Eyes With Corneal Ectatic Conditions
2020. "Safety and Efficacy of Corneal Crosslinking Using the PXL-Platinum 330 for Eyes With Corneal Ectatic Conditions". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04240457.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top